Skip to main content
SpringerLink
Log in
Book cover

Surgical Intensive Care Medicine pp 379–387Cite as

Blood Products

  • Chapter

  • 3046 Accesses

Abstract

Blood components, commonly transfused in the intensive care unit (ICU), include packed red blood cells, platelets, plasma, and cryoprecipitate. The indications, dosing, and expectations for each will be discussed, in turn. Components occasionally transfused include albumin and factor concentrates. Although some indications of the latter are controversial and extensive discussions are beyond the scope of this chapter, a brief mention of their use is warranted.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine. First of two parts – blood transfusion. N Engl J Med. 1999;340:438–447.

    Article  PubMed  CAS  Google Scholar 

  2. Anonymous. Practice guidelines for blood component therapy: a report by the American Society of Anesthesiologists Task Force on Blood Component Therapy. Anesthesiology. 1996;84:732–747.

    Google Scholar 

  3. Anonymous. Practice guidelines for perioperative blood transfusion and adjuvant therapies: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies. Anesthesiology. 2006;105:198–208.

    Google Scholar 

  4. Hebert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med. 1999;340:409–417.

    Article  PubMed  CAS  Google Scholar 

  5. Napolitano LM. Current status of blood component therapy in surgical critical care. Curr Opin Crit Care. 2004;10:311–317.

    Article  PubMed  Google Scholar 

  6. Vincent JL, Piagnerelli M. Transfusion in the intensive care unit. Crit Care Med. 2006;34(Suppl):S96–S101.

    Article  PubMed  Google Scholar 

  7. Vallet B, Adamczyk S, Barreau O, Lebuffe G. Physiologic transfusion triggers. Best Pract Res Clin Anaesthesiol. 2007;21:173–181.

    Article  PubMed  CAS  Google Scholar 

  8. Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine. Second of two parts – blood conservation. N Engl J Med. 1999;340:525–533.

    Article  PubMed  CAS  Google Scholar 

  9. Reid TJ. Hb-based oxygen carriers: are we there yet? Transfusion. 2003;43:280–287.

    Article  PubMed  CAS  Google Scholar 

  10. Natanson C, Kern SJ, Lurie P, Banks SM, Wolfe SM. Cell-free hemoglobin based blood substitutes and risk of myocardial infarction and death: meta-analysis. JAMA. 2008;299:2304–2312.

    Article  PubMed  CAS  Google Scholar 

  11. Anonymous. Practice parameter for the use of fresh-frozen plasma, cryoprecipitate, and platelets. Fresh-Frozen Plasma, Cryoprecipitate, and Platelets Administration Practice Guidelines Development Task Force of the College of American Pathologists. JAMA 1994;271:777–781.

    Google Scholar 

  12. Dzik WH. Component therapy before bedside procedures. In: Mintz PD, editor. Transfusion therapy: clinical principles and practice. 2nd ed. Bethesda, MD: AABB Press; 2005. p. 1–26.

    Google Scholar 

  13. O’Shaughnessy DF, Atterbury C, Bolton Maggs P, et al. British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol. 2004;126:11–28.

    Google Scholar 

  14. Segal JB, Dzik WH. Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review. Transfusion. 2005;45:1413–1425.

    Article  PubMed  Google Scholar 

  15. Erstad BL, Gales BJ, Rappaport WD. The use of albumin in clinical practice. Arch Intern Med. 1991;151:901–911.

    Article  PubMed  CAS  Google Scholar 

  16. Vermeulen LC, Ratko TA, Erstad BL, Brecher ME, Matuszewski KA. A paradigm for consensus. The University Hospital Consortium guidelines for the use of albumin, nonprotein colloid, and crystalloid solutions. Arch Intern Med. 1995;155:373–379.

    Article  PubMed  Google Scholar 

  17. Anonymous. Human albumin administration in critically ill patients: a systematic review of randomized controlled trials. Cochrane Injuries Group Albumin Reviewers. Br Med J. 1998;317:235–240.

    Google Scholar 

  18. Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R. SAFE Study Investigators. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. 2004;350:2247–2256.

    Article  PubMed  CAS  Google Scholar 

  19. Lusher JM. Congenital disorders of clotting proteins and their management. In: Simon TL, Dzik WH, Snyder EL, Stowell CP, Strauss RG, editors. Rossi’s principles of transfusion medicine. 3rd ed. Philadelphia: Lippincott Williams and Wilkins; 2002. p. 448–462.

    Google Scholar 

  20. Mannucci PM. Treatment of von Willebrand’s disease. N Engl J Med. 2004;351:683–694.

    Article  PubMed  CAS  Google Scholar 

  21. Lane TA, Anderson KC, Goodnough LT, et al. Leukocyte reduction in blood component therapy. Ann Intern Med. 1992;117:151–162.

    Article  PubMed  CAS  Google Scholar 

  22. Laupacis A, Brown J, Costello B, et al. Prevention of posttransfusion CMV in the era of universal WBC reduction: a consensus statement. Transfusion. 2001;41:560–569.

    Article  PubMed  CAS  Google Scholar 

  23. Moroff G, Luban NL. The irradiation of blood and blood components to prevent graft-versus-host disease: technical issues and guidelines. Transfus Med Rev. 1997;11:15–26.

    Article  PubMed  CAS  Google Scholar 

  24. Davenport RD, Burnie KL, Barr RM. Transfusion management of patients with IgA deficiency and anti-IgA during liver transplantation. Vox Sang. 1992;63:247–250.

    Article  PubMed  CAS  Google Scholar 

  25. AuBuchon JP, Kruskall MS. Transfusion safety: realigning efforts with risks. Transfusion. 1997;37:1211–1216.

    Article  PubMed  CAS  Google Scholar 

  26. Sazama K. Reports of 355 transfusion-associated deaths: 1976–1985. Transfusion. 1990;30:583–590.

    Article  PubMed  CAS  Google Scholar 

  27. Boyan CP, Howland WS. Cardiac arrest and temperature of bank blood. JAMA. 1963;183:58–60.

    Article  PubMed  CAS  Google Scholar 

  28. Ryden SE, Oberman HA. Compatibility of common intravenous solutions with CPD blood. Transfusion. 1975;15:250–255.

    Article  PubMed  CAS  Google Scholar 

  29. Oberman HA, Barnes BA, Friedman BA. The risk of abbreviating the major crossmatch in urgent or massive transfusion. Transfusion. 1978;18:137–141.

    Article  PubMed  CAS  Google Scholar 

  30. Winslow RM. New transfusion strategies: red cell substitutes. Annu Rev Med. 1999;50:337–353.

    Article  PubMed  CAS  Google Scholar 

  31. Olsson ML, Clausen H. Modifying the red cell surface: towards an ABO-universal blood supply. Br J Haematol. 2008;140:3–12.

    PubMed  CAS  Google Scholar 

  32. Collins JA. Problems associated with the massive transfusion of stored blood. Surgery. 1974;75:274–295.

    PubMed  CAS  Google Scholar 

  33. Mannucci PM, Federici AB, Sirchia G. Hemostasis testing during massive blood replacement. A study of 172 cases. Vox Sang. 1982;42:113–123.

    Article  PubMed  CAS  Google Scholar 

  34. Duchesne JC, Hunt JP, Wahl G, et al. Review of current blood transfusions strategies in a mature level I trauma center: were we wrong for the last 60 years? J Trauma. 2008;65:272–278.

    Article  PubMed  Google Scholar 

  35. Gunter OL, Au BK, Isbell JM, Mowery NT, Young PP, Cotton BA. Optimizing outcomes in damage control resuscitation: identifying blood product ratios associated with improved survival. J Trauma. 2008;65:527–534.

    Article  PubMed  Google Scholar 

  36. Hardy JF, DeMoerloose P, Samama M. Massive transfusion and coagulopathy: pathophysiology and implications for clinical management. Can J Anaesth. 2004;51:293–310.

    Article  PubMed  Google Scholar 

  37. Ciavarella D, Reed RL, Counts RB, et al. Clotting factor levels and the risk of diffuse microvascular bleeding in the massively transfused patient. Br J Haematol. 1987;67:365–368.

    Article  PubMed  CAS  Google Scholar 

  38. Roberts HR, Monroe DM, White GC. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood. 2004;104:3858–3864.

    Article  PubMed  CAS  Google Scholar 

  39. Goodnough LT, Lublin DM, Zhang L, Despotis G, Eby C. Transfusion medicine service policies for recombinant factor VIIa administration. Transfusion. 2004;44:1325–1331.

    Article  PubMed  CAS  Google Scholar 

  40. Dutton RP, McCunn M, Hyder M, et al. Factor VIIa for correction of traumatic coagulopathy. J Trauma. 2004;57:709–719.

    Article  PubMed  CAS  Google Scholar 

  41. Boffard KD, Riou B, Warren B, et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma. 2005;59:8–18.

    Article  PubMed  CAS  Google Scholar 

  42. O’Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA. 2006;295:293–298.

    Article  PubMed  Google Scholar 

  43. Bracey A, Harrison C, Weiskopf R, Sipherd B, Steiner EA. Guidelines for massive transfusion. Bethesda, MD: AABB; 2005.

    Google Scholar 

  44. Perkins HA, Payne R, Ferguson J, Wood M. Nonhemolytic febrile transfusion reactions. Quantitative effects of blood components with emphasis on isoantigenic incompatibility of leukocytes. Vox Sang. 1966;11:578–600.

    Article  PubMed  CAS  Google Scholar 

  45. Heddle NM, Kelton JG. Febrile nonhemolytic transfusion reactions. In: Popovsky MA, editor. Transfusion reactions. 2nd ed. Bethesda, MD: AABB Press; 2001. p. 45–82.

    Google Scholar 

  46. Vamvakas EC, Pineda AA. Allergic and anaphylactic reactions. In: Popovsky MA, editor. Transfusion reactions. 2nd ed. Bethesda, MD: AABB Press; 2001. p. 83–127.

    Google Scholar 

  47. Sandler SG, Mallory D, Malamut D, Eckrich R. IgA anaphylactic transfusion reactions. Transfus Med Rev. 1995;9:1–8.

    Article  PubMed  CAS  Google Scholar 

  48. Silliman CC. The two-event model of transfusion-related acute lung injury. Crit Care Med. 2006;34(Suppl):S124–S131.

    Article  PubMed  Google Scholar 

  49. Davenport RD. Hemolytic transfusion reactions. In: Popovsky MA, editor. Transfusion reactions. 2nd ed. Bethesda, MD: AABB Press; 2001. p. 1–44.

    Google Scholar 

  50. Perez P, Salmi LR, Follea G, et al. Determinants of transfusion-associated bacterial contamination: results of the French BACTHEM Case-Control Study. Transfusion. 2001;41:862–872.

    Article  PubMed  CAS  Google Scholar 

  51. Kuehnert MJ, Roth VR, Haley NR, et al. Transfusion-transmitted bacterial infection in the United States, 1998 through 2000. Transfusion. 2001;41:1493–1499.

    Article  PubMed  CAS  Google Scholar 

  52. Popovsky MA, Audet AM, Andrzejewski C. Transfusion-associated circulatory overload in orthopedic surgery patients: a multi-institutional study. Immunohematology. 1996;12:87–89.

    PubMed  CAS  Google Scholar 

  53. Ness PM, Shirey RS, Thoman SK, Buck SA. The differentiation of delayed serologic and delayed hemolytic transfusion reactions: incidence, long-term serologic findings, and clinical significance. Transfusion. 1990;30:688–693.

    Article  PubMed  CAS  Google Scholar 

  54. Heddle NM, Soutar RL, O’Hoski PL, et al. A prospective study to determine the frequency and clinical significance of alloimmunization post-transfusion. Br J Haematol. 1995;91:1000–1005.

    Article  PubMed  CAS  Google Scholar 

  55. Petz LD, Garratty G, Calhoun L, et al. Selecting donors of platelets for refractory patients on the basis of HLA antibody specificity. Transfusion. 2000;40:1446–1456.

    Article  PubMed  CAS  Google Scholar 

  56. O’Connell BA, Schiffer CA. Donor selection for alloimmunized patients by platelet crossmatching of random-donor platelet concentrates. Transfusion. 1990;30:314–317.

    Article  PubMed  Google Scholar 

  57. Anonymous. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. N Engl J Med. 1997;337:1861–1869.

    Google Scholar 

  58. Anderson KC, Weinstein HJ. Transfusion-associated graft-versus-host disease. N Engl J Med. 1990;323:315–321.

    Article  PubMed  CAS  Google Scholar 

  59. Linden JV, Pisciotto PT. Transfusion-associated graft-versus-host disease and blood irradiation. Transfus Med Rev. 1992;6:116–123.

    Article  PubMed  CAS  Google Scholar 

  60. Raghavan M, Marik PE. Anemia, allogenic blood transfusion, and immunomodulation in the critically ill. Chest. 2005;127:295–307.

    Article  PubMed  Google Scholar 

  61. Busch MP, Kleinman SH, Nemo GJ. Current and emerging infectious risks of blood transfusions. JAMA. 2003;289:959–962.

    Article  PubMed  Google Scholar 

  62. Busch MP, Caglioti S, Robertson EF, et al. Screening the blood supply for West Nile virus RNA by nucleic acid amplification testing. N Engl J Med. 2005;353:460–467.

    Article  PubMed  CAS  Google Scholar 

  63. Fiebig EW, Busch MP. Infectious disease screening. In: Roback JD, Combs MR, Grossman BJ, Hillyer CD, editors. Technical manual. 16th ed. Bethesda, MD: AABB; 2008. p. 241–282.

    Google Scholar 

  64. Becker J, Blackall D, Evans C, et al. Guidelines for blood utilization review. Bethesda, MD: AABB; 2001.

    Google Scholar 

  65. Mintz PD. Quality assessment and improvement of blood transfusion practices. In: Mintz PD, editor. Transfusion therapy: clinical principles and practice. 2nd ed. Bethesda, MD: AABB Press; 2005. p. 609–629.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Transfusion Medicine, Department of Laboratory Medicine, Lahey Clinic Medical Center, Burlington, MA, USA

    Kurt F. Heim MD, PhD (Director)

Authors
  1. Kurt F. Heim MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Surgical Critical Care Division of Surgery, The Lahey Clinic Medical Center, Burlington, MA, USA

    John M. O’Donnell (Director, Surgical Intensive Care Unit Chairman) (Director, Surgical Intensive Care Unit Chairman)

  2. University Hospital Intensive Care Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil

    Flávio E. Nácul

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Heim, K.F. (2010). Blood Products. In: O’Donnell, J.M., Nácul, F.E. (eds) Surgical Intensive Care Medicine. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-77893-8_34

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-77893-8_34

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-77892-1

  • Online ISBN: 978-0-387-77893-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation